Hepatitis C News and Research

Latest Hepatitis C News and Research

FixHepC Buyers Club exposes weakness in Australian healthcare, assists patients to import life saving medication

In one of the greatest advances in medicine in decades, Hepatitis C is now largely curable. Over 200,000 Australians suffer from Hepatitis C. However the US manufacturer, Gilead Sciences Inc is attempting to charge the PBS $84,000 for a 12 week course of medication that costs under $200 dollars to manufacture.

13 Nov 2015

Montefiore and Einstein researchers awarded $14 million PCORI grant for hepatitis C research

A research team at Montefiore Health System and Albert Einstein College of Medicine led by Alain Litwin, M.D., was awarded $14 million by the Patient-Centered Outcomes Research Institute (PCORI) to determine how best to treat hepatitis C among people who inject drugs (PWID), a group with a high rate of infection.

11 Nov 2015

ACR releases 2015 Guideline for Treatment of Rheumatoid Arthritis

The American College of Rheumatology (ACR) released its 2015 Guideline for the Treatment of Rheumatoid Arthritis (RA) during the 2015 ACR/ARHP Annual Meeting in San Francisco.

11 Nov 2015

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

MPP announces expansion of mandate to hepatitis C and TB medicines

The Medicines Patent Pool, the world's only voluntary licensing mechanism in public health, announced an expansion of its mandate today to hepatitis C and tuberculosis medicines. The UNITAID Executive Board, meeting November 4-5 in Geneva, approved the MPP's proposals to improve access to both life-saving direct acting antivirals (DAAs) to treat hepatitis C and new and re-purposed medicines for tuberculosis.

6 Nov 2015

Genvoya approved as complete regimen for HIV treatment

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

6 Nov 2015

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Johnson & Johnson today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.

4 Nov 2015

Study provides novel insight into the evolution of hepatitis A virus and how it spreads to humans

Researchers at the University of North Carolina at Chapel Hill are part of an international team led by the University of Bonn, Germany, who have found a link between the origin of hepatitis A virus (HAV) and small mammals.

4 Nov 2015

HIV, Ebola appear to be of animal origin

The hepatitis A virus can trigger acute liver inflammation which generally has a mild course in small children but which can become dangerous in adults.

3 Nov 2015

New paper device could rapidly and inexpensively assess hepatitis B, male infertility

Scientists have developed a new paper device that analyzes DNA and could rapidly and inexpensively assess disparate conditions including hepatitis B and male infertility, which together affect millions of people around the world. The test, reported in the Journal of the American Chemical Society, could be of particular help diagnosing people in low-income areas.

29 Oct 2015

Researchers report new way to help improve vaccines using molecules that direct the immune system

As the days get colder and shorter, we carve jack-o-lanterns and drink pumpkin spice lattes. But one fall tradition can actually keep you healthy: getting your flu shot. Like all vaccines, the flu shot trains the immune system to fend off infection, but some need help to produce the full effect.

29 Oct 2015

Hiroshima University researchers report promising new avenue for treating hepatitis B

A promising new avenue for treating hepatitis B has been reported by researchers at Hiroshima University who have developed a new animal model of the disease.

28 Oct 2015

Researchers uncover genes that can suppress HCV infection within the liver

University of Adelaide researchers have uncovered the role played by a family of genes, which can suppress hepatitis C virus (HCV) infection within the liver.

28 Oct 2015

Drug engineered from bananas could fight off wide range of viruses

A banana a day may not keep the doctor away, but a substance originally found in bananas and carefully edited by scientists could someday fight off a wide range of viruses, new research suggests.

23 Oct 2015

CDC publishes reports on infectious and noninfectious diseases

Beginning with the Oct. 23, 2015, Supplements to Morbidity and Mortality Weekly Report (MMWR), CDC will publish the summaries of all notifiable conditions – infectious and noninfectious – at the same time.

23 Oct 2015

NHS Trusts not compliant with safer sharps rules two years after regulation enacted, says new MindMetre reseach

New research from independent research organization MindMetre has revealed that many NHS Trusts are not complying with ‘safer sharps’ rules, putting NHS employees at unnecessary risk of ‘needlestick’ injuries and possible blood-borne infections such as hepatitis and HIV.

22 Oct 2015

Drug interactions in placenta may increase risk of birth defects or stunting fetal growth

To date, studies in pregnant women examining transport of drugs across the placenta are rare and inadequate, said Tomo Nabekura, PhD. Such knowledge could be vital to preserving fetal health. In a new laboratory study, Nabekura and colleagues have illuminated a piece of this puzzle, and the results hint that mothers taking new anti-hepatitis C and/or anti-HIV drugs along with anti-hypertensives or non-steroidal anti-inflammatories (NSAIDs) could be raising the risk of birth defects or stunting fetal growth, respectively.

15 Oct 2015

Investigational antiviral drug effectively treats Lassa virus infection in guinea pigs

Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study from National Institutes of Health scientists and colleagues.

13 Oct 2015

Men on effective HIV therapy less likely to get HBV infection, shows research

Previous studies of individuals with HIV have suggested that HIV drug regimens that included drugs active against hepatitis B virus (HBV) can decrease the risk of infection with the liver-damaging HBV.

13 Oct 2015

Hepatitis C News and Research

Latest Hepatitis C News and Research

FixHepC Buyers Club exposes weakness in Australian healthcare, assists patients to import life saving medication

Montefiore and Einstein researchers awarded $14 million PCORI grant for hepatitis C research

ACR releases 2015 Guideline for Treatment of Rheumatoid Arthritis

New funding for Centenary's life saving research

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

MPP announces expansion of mandate to hepatitis C and TB medicines

Genvoya approved as complete regimen for HIV treatment

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Study provides novel insight into the evolution of hepatitis A virus and how it spreads to humans

HIV, Ebola appear to be of animal origin

New paper device could rapidly and inexpensively assess hepatitis B, male infertility

Researchers report new way to help improve vaccines using molecules that direct the immune system

Hiroshima University researchers report promising new avenue for treating hepatitis B

Researchers uncover genes that can suppress HCV infection within the liver

Drug engineered from bananas could fight off wide range of viruses

CDC publishes reports on infectious and noninfectious diseases

NHS Trusts not compliant with safer sharps rules two years after regulation enacted, says new MindMetre reseach

Drug interactions in placenta may increase risk of birth defects or stunting fetal growth

Investigational antiviral drug effectively treats Lassa virus infection in guinea pigs

Men on effective HIV therapy less likely to get HBV infection, shows research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in